がんワクチンの世界市場レポート 2025年

がんワクチンの市場規模は、今後数年で急成長が見込まれます。2029年には138億9,000万米ドルに成長し、CAGRは13.9%となります。予測期間の成長は、がんワクチンとの併用療法、製薬会社による投資の増加、バイオマーカーの台頭、個別化ワクチン、ワクチン接種プログラムの拡大などに起因すると考えられます。予測期間の主な動向には、免疫学の進歩、アジュバント療法、適応症の多様化、患者アクセス、共同研究、新抗原ベースのワクチン、治療的ながんワクチンなどが含まれます。

予測される世界のがん患者の増加は、予測期間を通じてがんワクチン市場の拡大を促進すると予測されています。米国がん協会（American Cancer Society）の2022年1月の報告書によると、米国だけでも190万人の新規がん診断と60万9,360人のがん関連死亡が予測されています。特に肺がん、前立腺がん、腸がん、女性乳がんなどの顕著なタイプのがんが急増し、世界の新規症例の43％を占めていることから、がんワクチンの需要は今後数年間でさらに高まると予想されます。

がんワクチン市場の成長が期待される背景には、研究開発に対する政府予算の増加があります。政府の資金援助は、科学的な取り組み、医療インフラ、治療へのアクセス改善などに資金を提供することで、がん研究と治療の発展に重要な役割を果たしています。2023年9月に米国議会から73億米ドル（前年比4億800万米ドル増）の予算を受け取った国立がん研究所は、この動向を反映しています。研究開発に対するこのような政府支援の流入は、がんワクチン市場の上昇軌道に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のがんワクチン市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のがんワクチン市場：成長率分析
• 世界のがんワクチン市場の実績：規模と成長、2019～2024年
• 世界のがんワクチン市場の予測：規模と成長、2024～2029年、2034年
• 世界のがんワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のがんワクチン市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• がん予防ワクチン
• 治療用がんワクチン
• 世界のがんワクチン市場：技術別、実績と予測、2019～2024年、2024～2029年、2034年
• 樹状細胞（DC）がんワクチン
• 組み換えがんワクチン
• 抗原/アジュバントがんワクチン
• 細胞全体がんワクチン
• ウイルスベクターとDNAがんワクチン
• 世界のがんワクチン市場：がんタイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 前立腺
• 子宮頸部
• 大腸
• 咽喉
• その他
• 世界のがんワクチン市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• がん治療センター
• 研究機関
• 世界のがんワクチン市場：がん予防ワクチンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• HPVワクチン
• B型肝炎ワクチン
• 世界のがんワクチン市場：治療用がんワクチンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• シプロイセルT（プロベンジ）
• タリモジーン・ラヘルパレプベク（T-VEC）
• その他

第7章 地域別・国別分析

• 世界のがんワクチン市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のがんワクチン市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• がんワクチン市場：競合情勢
• がんワクチン市場：企業プロファイル
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Aduro Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Dendreon Corporation Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Astellas Pharma Inc.
• Sanofi SA
• Sanpower Group
• CSL Limited
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• Advantagene Inc.
• Advaxis Inc.
• Agenus Inc.
• Altor BioScience Corporation
• Argos Therapeutics Inc.
• Oncothyreon Inc.
• Oncovir Inc.
• Oxford BioMedica plc
• Prima BioMed Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• がんワクチン市場2029：新たな機会を提供する国
• がんワクチン市場2029：新たな機会を提供するセグメント
• がんワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Cancer vaccines encompass preventive and therapeutic vaccinations intended to aid the body in preventing illness and treating cancer. These vaccines aim to instruct the immune system to identify and eliminate harmful microbes and cells.

They are broadly categorized into preventive and therapeutic cancer vaccines. Therapeutic vaccines assist the immune system in recognizing viruses or malignant cells. Various technologies, including dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, whole cell cancer vaccines, viral vectors, and DNA cancer vaccines, are employed across different types of cancers like prostate, cervical, colorectal, throat, and others. These innovations operate within sectors like cancer treatment centers and research institutes.

The cancer vaccines market research report is one of a series of new reports from The Business Research Company that provide cancer vaccines market statistics, such as cancer vaccines industry global market size, regional shares, competitors with a cancer vaccines market share, detailed cancer vaccines market segments, market trends and opportunities, and any other information you may require to thrive in the cancer vaccines industry. This cancer vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cancer vaccines market size has grown rapidly in recent years. It will grow from $7.22 billion in 2024 to $8.25 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to the rising incidence of cancer, increasing awareness of cancer vaccines, expanding range of approved cancer vaccines, growing evidence of the efficacy of cancer vaccines, and government support for research and development.

The cancer vaccines market size is expected to see rapid growth in the next few years. It will grow to $13.89 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth in the forecast period can be attributed to combination therapies with cancer vaccines, increased investment from pharmaceutical companies, emerging biomarkers, personalized vaccines, expanding vaccination programs. Major trends in the forecast period include advancements in immunology, adjuvant therapies, diversification of indications, patient access, collaborative research, neoantigen-based vaccines, and therapeutic cancer vaccines.

The projected escalation in global cancer cases is anticipated to fuel expansion within the cancer vaccines market throughout the forecast period. As per the American Cancer Society's January 2022 report, an estimated 1.9 million new cancer diagnoses and 609,360 cancer-related deaths are expected in the US alone. This surge in cancer prevalence, notably in prominent types like lung, prostate, bowel, and female breast cancer, collectively accounting for 43% of new cases worldwide, is expected to spur demand for cancer vaccines in the years ahead.

Anticipated growth in the cancer vaccines market is driven by amplified government allocations for research and development efforts. Government funding, instrumental in advancing cancer research and treatment, plays a pivotal role by financing scientific endeavors, medical infrastructure, and improved access to care. The National Cancer Institute, receiving a $7.3 billion budget in September 2023 from the United States Congress-an increase of $408 million from the previous year-reflects this trend. This influx of government support for research and development significantly contributes to the upward trajectory of the cancer vaccines market.

Companies within the cancer vaccines sector are progressively investing in preventive or prophylactic vaccine development aimed at averting cancer incidence. Prophylactic vaccines, intended to bolster immunity, introduce antigens into the body. Notably, cervical cancer ranks as the second-most common cancer among women globally, prompting the availability of three HPV vaccines for prophylactic use. Merck's Gardasil and Gardasil 9, along with GSK's Cervarix, collectively provide protection against HPV types responsible for a substantial majority of cervical cancers, including HPV 16, 18, and additional oncogenic types.

Key players in the cancer vaccines industry are directing their focus towards introducing quadrivalent vaccines to optimize market revenue. These vaccines offer protection against multiple strains of specific viruses or bacteria. Serum Institute of India's launch of CERVAVAC in January 2023 exemplifies this trend, presenting the first indigenous cervical cancer vaccine designed to combat HPV types 16, 18, 6, and 11 accounting for a significant portion of cervical cancers. Administered in either two or three doses depending on age, this vaccine aims to maximize prevention within the specified demographic.

In March 2022, NEC OncoImmunity (NOI), a biotechnology company headquartered in Norway, completed the acquisition of neoantigen vaccine development assets from Vaximm AG, a Switzerland-based biotech firm. The financial details of this transaction were not disclosed. This strategic acquisition is anticipated to empower NOI in advancing its AI-driven and personalized treatment strategies tailored for combating cancer. Vaximm AG specializes in manufacturing vaccines and T-cell immunotherapies designed to aid patients battling cancer.

Major companies operating in the cancer vaccines market include GlaxoSmithKline plc, Merck & Co. Inc., Aduro Biotech Inc., AstraZeneca PLC, Dendreon Corporation, Astellas Pharma Inc., Sanofi SA, Sanpower Group, CSL Limited, Pfizer Inc., Serum Institute of India Pvt. Ltd., Advantagene Inc., Advaxis Inc., Agenus Inc., Altor BioScience Corporation, Argos Therapeutics Inc., Oncothyreon Inc., Oncovir Inc., Oxford BioMedica plc., Prima BioMed Ltd., Sotio LLC, Transgene SA, Ubivac LLC, Vaccinogen and Vaxon Biotech, Bavarian Nordic A/S, Bharat Biotech International Limited, Bristol-Myers Squibb Company, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Galena Biopharma Inc., Moderna Inc., Biothera Pharmaceuticals Inc., Celldex Therapeutics Inc., Genexine Inc., Gritstone Oncology Inc., Heat Biologics Inc., ISA Pharmaceuticals B.V., Northwest Biotherapeutics Inc., OncBioMune Pharmaceuticals Inc., TapImmune Inc., Vaxil Bio Ltd., VBI Vaccines Inc., Ziopharm Oncology Inc.

North America was the largest region in the cancer vaccines market in 2024. The regions covered in the cancer vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cancer vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The cancer vaccines market consists of sales of Bacillus calmette-guerin, Sipuleucel-T, and Human Papillomavirus (HPV) vaccines. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer vaccines market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Preventive Cancer Vaccines; Therapeutic Cancer Vaccines
• 2) By Technology: Dendritic Cells (DC) Cancer Vaccines; Recombinant Cancer Vaccines; Antigen/Adjuvant Cancer Vaccines; Whole Cell Cancer Vaccines; Viral Vector & DNA Cancer Vaccines
• 3) By Cancer Type: Prostate; Cervical; Colorectal; Throat; Other Cancer Types
• 4) By End-User: Cancer Treatment Centers; Research Institutes
• Subsegments:
• 1) By Preventive Cancer Vaccines: HPV Vaccines; Hepatitis B Vaccines
• 2) By Therapeutic Cancer Vaccines: Sipuleucel-T (Provenge); Talimogene Laherparepvec (T-VEC); Other Therapeutic Vaccines
• Companies Mentioned: GlaxoSmithKline plc; Merck & Co. Inc.; Aduro Biotech Inc.; AstraZeneca PLC; Dendreon Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Vaccines Market Characteristics

3. Cancer Vaccines Market Trends And Strategies

4. Cancer Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Cancer Vaccines Growth Analysis And Strategic Analysis Framework

• 5.1. Global Cancer Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Cancer Vaccines Market Growth Rate Analysis
• 5.4. Global Cancer Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Cancer Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Cancer Vaccines Total Addressable Market (TAM)

6. Cancer Vaccines Market Segmentation

• 6.1. Global Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Preventive Cancer Vaccines
• Therapeutic Cancer Vaccines
• 6.2. Global Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dendritic Cells (DC) Cancer Vaccines
• Recombinant Cancer Vaccines
• Antigen/Adjuvant Cancer Vaccines
• Whole Cell Cancer Vaccines
• Viral Vector & DNA Cancer Vaccines
• 6.3. Global Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Prostate
• Cervical
• Colorectal
• Throat
• Other Cancer Types
• 6.4. Global Cancer Vaccines Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment Centers
• Research Institutes
• 6.5. Global Cancer Vaccines Market, Sub-Segmentation Of Preventive Cancer Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• HPV Vaccines
• Hepatitis B Vaccines
• 6.6. Global Cancer Vaccines Market, Sub-Segmentation Of Therapeutic Cancer Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sipuleucel-T (Provenge)
• Talimogene Laherparepvec (T-VEC)
• Other Therapeutic Vaccines

7. Cancer Vaccines Market Regional And Country Analysis

• 7.1. Global Cancer Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Cancer Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Vaccines Market

• 8.1. Asia-Pacific Cancer Vaccines Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Vaccines Market

• 9.1. China Cancer Vaccines Market Overview
• 9.2. China Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Vaccines Market

• 10.1. India Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Vaccines Market

• 11.1. Japan Cancer Vaccines Market Overview
• 11.2. Japan Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Vaccines Market

• 12.1. Australia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Vaccines Market

• 13.1. Indonesia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Vaccines Market

• 14.1. South Korea Cancer Vaccines Market Overview
• 14.2. South Korea Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Vaccines Market

• 15.1. Western Europe Cancer Vaccines Market Overview
• 15.2. Western Europe Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Vaccines Market

• 16.1. UK Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Vaccines Market

• 17.1. Germany Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Vaccines Market

• 18.1. France Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Vaccines Market

• 19.1. Italy Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Vaccines Market

• 20.1. Spain Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Vaccines Market

• 21.1. Eastern Europe Cancer Vaccines Market Overview
• 21.2. Eastern Europe Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Vaccines Market

• 22.1. Russia Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Vaccines Market

• 23.1. North America Cancer Vaccines Market Overview
• 23.2. North America Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Vaccines Market

• 24.1. USA Cancer Vaccines Market Overview
• 24.2. USA Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Vaccines Market

• 25.1. Canada Cancer Vaccines Market Overview
• 25.2. Canada Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Vaccines Market

• 26.1. South America Cancer Vaccines Market Overview
• 26.2. South America Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Vaccines Market

• 27.1. Brazil Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Vaccines Market

• 28.1. Middle East Cancer Vaccines Market Overview
• 28.2. Middle East Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Vaccines Market

• 29.1. Africa Cancer Vaccines Market Overview
• 29.2. Africa Cancer Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Cancer Vaccines Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Cancer Vaccines Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Vaccines Market Competitive Landscape And Company Profiles

• 30.1. Cancer Vaccines Market Competitive Landscape
• 30.2. Cancer Vaccines Market Company Profiles
  • 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Aduro Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Dendreon Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Vaccines Market Other Major And Innovative Companies

• 31.1. Astellas Pharma Inc.
• 31.2. Sanofi SA
• 31.3. Sanpower Group
• 31.4. CSL Limited
• 31.5. Pfizer Inc.
• 31.6. Serum Institute of India Pvt. Ltd.
• 31.7. Advantagene Inc.
• 31.8. Advaxis Inc.
• 31.9. Agenus Inc.
• 31.10. Altor BioScience Corporation
• 31.11. Argos Therapeutics Inc.
• 31.12. Oncothyreon Inc.
• 31.13. Oncovir Inc.
• 31.14. Oxford BioMedica plc
• 31.15. Prima BioMed Ltd.

32. Global Cancer Vaccines Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Vaccines Market

34. Recent Developments In The Cancer Vaccines Market

35. Cancer Vaccines Market High Potential Countries, Segments and Strategies

• 35.1 Cancer Vaccines Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Cancer Vaccines Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Cancer Vaccines Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer